{'fraction_non_alphanumeric': 0.035381239714755895, 'fraction_numerical': 0.01426220515633571, 'mean_word_length': 5.15008431703204, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
210P Worsening of breast cancer patients’ condition: What happened during COVID-19? A meta-analysis

Background: COVID-19 has impacted every aspect of our lives. Flooding of hospitals with COVID-19 patients have affected quality of care given to breast cancer patients. Our aim is to assess the impact of COVID-19 on presenting cases of breast cancer and worsening of breast cancer stage and/or TNM classification.

Background: We explored the impact, and estimated the clinical importance, of sensory and motor Taxane-Induced Peripheral Neuropathy (TIPN) symptoms on Health-Related Quality of Life (HRQOL) among Early-Stage Breast Cancer Survivors (ESBCS).
Methods: A population-based cohort of 884 residual-free ESBCS in Southeast Sweden received a postal questionnaire including the EORTC chemotherapy-induced PN (CIPN20) and the EORTC QLQ-C30 instruments. Mean scores of QOL subscales among ESBCS with and without TIPN were calculated and adjustments made for confounding factors i.e., age, lifestyle factors and co-morbidities (linear regression analyses). The proportion of ESBCS with a clinically important impairment (CiI) of QOL using thresholds values proposed by Giesinger et al.
[1] was calculated. The mean difference in scores was categorized into four groups (trivial, small, medium, large) depending on their clinical relevance in accordance with guidelines reported by Cocks et al. [2].
Results: Response rate was 79%, 646 survivors were included in the analysis. In median 3.6 (1.5-7.3) years had elapsed since taxane treatment. The proportion of ESBCS reporting CiI increased with the level of severity. Among ESBCS with moderatesevere PN, 59.4-93.3% had CiI on physical function and 57.7-78.6% on emotional function. The impact of TIPN symptoms on global QOL worsened with increased level of severity. The significance level of P trend <0.001 was reached for all but two symptoms i.e., "difficulty distinguishing hot/cold water" and "cramps in feet". The largest clinically relevant effect on HRQOL was reported for moderate-severe "difficulty climbing stairs or getting out of chair because of weakness of legs" and "problems standing/walking because difficulty feeling ground under feet".
Conclusions: Persistent symptoms of sensory and motor TIPN is associated with clinically relevant detrimental effects on HRQOL among ESBC survivors. The proportion and size of clinically important impairment increased with level of severity.  Background: Financial toxicity(FT) refers to the harmful effects of the excess financial strain caused by a cancer diagnosis on the well-being of patients. With the continued escalation of cancer treatment costs, FT has become an important matter in recent cancer care. Breast cancer is considered a serious disease associated with a large medical and economic burden.
Methods: A survey containing 23 questions addressing the financial impact of oncological treatment and the Comprehensive Score for Financial Toxicity-COST, was applied on private institutions in Brazil. The relationship between those questions with the COST was evaluated by Linear regression. We considered variables with an influence on COST, those that were significant (p 0.05) on uni/multivariable approach.
Conclusions: This study found a major impact of oncological treatment on patients' finances. Large financial burdens have been found to adversely affect access to care and outcomes among cancer patients, the active development action to mitigate these effects among already vulnerable groups remains of key importance.
Legal entity responsible for the study: The authors.
Funding: Has not received any funding.